149 related articles for article (PubMed ID: 17075410)
1. Health-related quality-of-life study in patients with carcinoma of the thyroid after thyroxine withdrawal for whole body scanning.
Chow SM; Au KH; Choy TS; Lee SH; Yeung NY; Leung A; Leung A; Leung HL; Shek CC; Law SC
Laryngoscope; 2006 Nov; 116(11):2060-6. PubMed ID: 17075410
[TBL] [Abstract][Full Text] [Related]
2. Three-week thyroxine withdrawal thyroglobulin stimulation screening test to detect low-risk residual/recurrent well-differentiated thyroid carcinoma.
Golger A; Fridman TR; Eski S; Witterick IJ; Freeman JL; Walfish PG
J Endocrinol Invest; 2003 Oct; 26(10):1023-31. PubMed ID: 14759077
[TBL] [Abstract][Full Text] [Related]
3. Quality of life and effectiveness comparisons of thyroxine withdrawal, triiodothyronine withdrawal, and recombinant thyroid-stimulating hormone administration for low-dose radioiodine remnant ablation of differentiated thyroid carcinoma.
Lee J; Yun MJ; Nam KH; Chung WY; Soh EY; Park CS
Thyroid; 2010 Feb; 20(2):173-9. PubMed ID: 20151824
[TBL] [Abstract][Full Text] [Related]
4. Managing thyroid cancer without thyroxine withdrawal.
Rosário PW; Vasconcelos FP; Cardoso LD; Lauria MW; Rezende LL; Padrão EL; Barroso AL; Guimarães VC; Purisch S
Arq Bras Endocrinol Metabol; 2006 Feb; 50(1):91-6. PubMed ID: 16628280
[TBL] [Abstract][Full Text] [Related]
5. Rapid rise in serum thyrotropin concentrations after thyroidectomy or withdrawal of suppressive thyroxine therapy in preparation for radioactive iodine administration to patients with differentiated thyroid cancer.
Serhal DI; Nasrallah MP; Arafah BM
J Clin Endocrinol Metab; 2004 Jul; 89(7):3285-9. PubMed ID: 15240604
[TBL] [Abstract][Full Text] [Related]
6. Novel recombinant human thyroid-stimulating hormone in aiding postoperative assessment of patients with differentiated thyroid cancer-phase I/II study.
Lin YS; Yang H; Li XY; Wu LQ; Xu JG; Yang AM; Gao ZR; Ding Y; Zhang YQ; Chen K; Mu ZZ; Jia JM; Niu N; Sun D; Zhang X; Zhang SQ; Geng QQ; Zhang YJ; Chen FN; He BX
Eur J Nucl Med Mol Imaging; 2022 Oct; 49(12):4171-4181. PubMed ID: 35781600
[TBL] [Abstract][Full Text] [Related]
7. Preparation for radioactive iodine administration in differentiated thyroid cancer patients.
Liel Y
Clin Endocrinol (Oxf); 2002 Oct; 57(4):523-7. PubMed ID: 12354135
[TBL] [Abstract][Full Text] [Related]
8. Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation.
Barbaro D; Boni G; Meucci G; Simi U; Lapi P; Orsini P; Pasquini C; Piazza F; Caciagli M; Mariani G
J Clin Endocrinol Metab; 2003 Sep; 88(9):4110-5. PubMed ID: 12970272
[TBL] [Abstract][Full Text] [Related]
9. Comparison of conventional L-thyroxine withdrawal and moderate hypothyroidism in preparation for whole-body 131-I scan and thyroglobulin testing.
Marturano I; Russo M; Spadaro A; Latina A; Malandrino P; Regalbuto C
J Endocrinol Invest; 2015 Sep; 38(9):1017-22. PubMed ID: 26070652
[TBL] [Abstract][Full Text] [Related]
10. Radioiodine treatment of metastatic differentiated thyroid cancer in patients on L-thyroxine, using recombinant human TSH.
Lippi F; Capezzone M; Angelini F; Taddei D; Molinaro E; Pinchera A; Pacini F
Eur J Endocrinol; 2001 Jan; 144(1):5-11. PubMed ID: 11174831
[TBL] [Abstract][Full Text] [Related]
11. Does recombinant human thyrotropin-stimulated positron emission tomography with [18F]fluoro-2-deoxy-D-glucose improve detection of recurrence of well-differentiated thyroid carcinoma in patients with low serum thyroglobulin?
Vera P; Kuhn-Lansoy C; Edet-Sanson A; Hapdey S; Modzelewski R; Hitzel A; d'Anjou J; Basuyau JP
Thyroid; 2010 Jan; 20(1):15-23. PubMed ID: 20017617
[TBL] [Abstract][Full Text] [Related]
12. Quality of life comparison in thyroxine hormone withdrawal versus triiodothyronine supplementation prior to radioiodine ablation in differentiated thyroid carcinoma: a prospective cohort study in the Indian population.
Rajamanickam S; Chaukar D; Siddiq S; Basu S; D'Cruz A
Eur Arch Otorhinolaryngol; 2022 Apr; 279(4):2011-2018. PubMed ID: 34165625
[TBL] [Abstract][Full Text] [Related]
13. Serum thyrotropin (TSH) levels after recombinant human TSH injections in children and teenagers with papillary thyroid cancer.
Iorcansky S; Herzovich V; Qualey RR; Tuttle RM
J Clin Endocrinol Metab; 2005 Dec; 90(12):6553-5. PubMed ID: 16174712
[TBL] [Abstract][Full Text] [Related]
14. Comparison between remnant and red-marrow absorbed dose in thyroid cancer patients submitted to 131I ablative therapy after rh-TSH stimulation versus hypothyroidism induced by L-thyroxine withdrawal.
Vaiano A; Claudio Traino A; Boni G; Grosso M; Lazzeri P; Colato C; Davì MV; Francia G; Lazzeri M; Mariani G; Ferdeghini M
Nucl Med Commun; 2007 Mar; 28(3):215-23. PubMed ID: 17264781
[TBL] [Abstract][Full Text] [Related]
15. An easy schedule for postsurgical radioiodine administration in newly diagnosed differentiated thyroid carcinoma patients.
Lupoli GA; Poggiano MR; Panico A; Granieri L; Lupoli R; Cacciapuoti M; Lupoli G
Clin Endocrinol (Oxf); 2013 Jan; 78(1):145-51. PubMed ID: 22882239
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic accuracy of 131I scanning with recombinant human thyrotropin versus thyroid hormone withdrawal in a patient with metastatic thyroid carcinoma and hypopituitarism.
Ringel MD; Ladenson PW
J Clin Endocrinol Metab; 1996 May; 81(5):1724-5. PubMed ID: 8626823
[TBL] [Abstract][Full Text] [Related]
17. Three-week thyroxine withdrawal: a thyroid-specific quality of life study.
Davids T; Witterick IJ; Eski S; Walfish PG; Freeman JL
Laryngoscope; 2006 Feb; 116(2):250-3. PubMed ID: 16467714
[TBL] [Abstract][Full Text] [Related]
18. In thyroidectomized patients with thyroid cancer, a serum thyrotropin of 30 μU/mL after thyroxine withdrawal is not always adequate for detecting an elevated stimulated serum thyroglobulin.
Valle LA; Gorodeski Baskin RL; Porter K; Sipos JA; Khawaja R; Ringel MD; Kloos RT
Thyroid; 2013 Feb; 23(2):185-93. PubMed ID: 22978687
[TBL] [Abstract][Full Text] [Related]
19. Recombinant human thyrotropin (rhTSH) versus Levo-thyroxine withdrawal in radioiodine therapy of differentiated thyroid cancer patients: differences in abdominal absorbed dose.
Campennì A; Amato E; Laudicella R; Alibrandi A; Cardile D; Pignata SA; Trimarchi F; Ruggeri RM; Auditore L; Baldari S
Endocrine; 2019 Jul; 65(1):132-137. PubMed ID: 30875058
[TBL] [Abstract][Full Text] [Related]
20. Levothyroxine suppression of thyroglobulin in patients with differentiated thyroid carcinoma.
Wang PW; Wang ST; Liu RT; Chien WY; Tung SC; Lu YC; Chen HY; Lee CH
J Clin Endocrinol Metab; 1999 Dec; 84(12):4549-53. PubMed ID: 10599717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
